Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Immuneering Q1 EPS $(0.49) Misses $(0.46) Estimate

Author: Benzinga Newsdesk | May 07, 2024 05:02pm
Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.46) by 6.52 percent. This is a 3.92 percent increase over losses of $(0.51) per share from the same period last year.

Posted In: IMRX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist